HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk



The Endocrinology Network® Cardiology clinical resource center is a hub of news related to cardiovascular health that is relevant to clinicians interested in endocrinology. This page will host relevant content about cardiology and cardiovascular disease including guideline updates, new studies and breakthroughs, and clinical perspectives for practicing clinicians.

Real-World Data Links Rosuvastatin to Nephrotoxicity

July 22, 2022

An analysis of real-world EHR data from more than 900,000 statin users suggests use of rosuvastatin was associated with an 8% greater risk of hematuria, a 17% greater risk of proteinuria, and a 15% higher risk of developing kidney failure requiring replacement therapy such as dialysis or transplantation compared to atorvastatin use.

COVID-19 Infection Could Increase Risk of Developing Diabetes

July 19, 2022

An analysis of data from more than 450,000 patients in the UK details an 81% increase in the net incidence of diabetes in the first 4 weeks after contracting COVID-19, which remained elevated through weeks 5-12, compared to those who did not contract COVID-19.

PCOS Increases Risk for Cardiovascular Complications During Delivery

June 22, 2022

Data from a Johns Hopkins Medicine-led analysis provide insight into the risk of cardiovascular complications among women with polycystic ovary syndrome during delivery hospitalizations compared to their counterparts without PCOS.

Increased PFAS Exposure Linked to High Blood Pressure in Aging Women

June 18, 2022

According to a new study, cumulative exposure to PFAS during midlife can increase the risk of incident hypertension among women as they age, with those in the highest tertile of cumulative exposure at a 71% greater risk of developing hypertension.

Time to Rethink Metformin as First-Line Therapy? Perspective from ADA 2022

June 06, 2022

After new data from the Diabetes Prevention Program Outcomes Study suggested neither metformin nor lifestyle intervention addressed the cardiovascular risk in patients with prediabetes, we asked experts at ADA 2022 if it was time to rethink metformin as first-line therapy in type 2 diabetes.